Notice of Intent to Sole Source the Procurement of Weekly Delivery of Turkey, Chicken, Guinea Pig, and Horse Red Blood Cells
Archived on August 5, 2026. Original response deadline: . Full description on SAM.gov.
Overview
- Response deadline
- 3:00 PM EDT
- Posted
- July 28, 2026
- Notice type
- Combined Synopsis/Solicitation
- NAICS
- 325414: Biological Product (except Diagnostic) Manufacturing
- Agency
- Department of Health and Human ServicesCENTERS FOR DISEASE CONTROL AND PREVENTION
Notice details
- Office
- CDC OFFICE OF ACQUISITION SERVICES
- Last updated
- Oct 28, 2026
- First published
- Last updated on SAM.gov
Identifiers
- Solicitation number
- 75D301-26-R-73503
- Notice ID
- 7090e696bfe541a8985e0a3a26211c3a
Description
This is a combined synopsis/solicitation for a sole-source requirement.
The Centers for Disease Control and Prevention intends to award a sole source firm fixed price contract for weekly delivery of turkey, chicken, guinea pig, and horse red blood cells (RBCs) under product service code (PSC) 6505-Drugs and Biologicals and North American Industry Classification System (NAICS) code) 325414-Blood derivatives manufacturing, manufactured by Lampire Biological Laboratories for use in hemagglutination inhibition (HI) assays performed by the CDC- National Center for Immunization and Respiratory Diseases (NCIRD)-Influenza Division. The required capability is the ability to consistently provide RBCs with the biological performance characteristics necessary to support validated HI assay methods and maintain continuity of CDC influenza surveillance data.
The required RBCs must be produced using manufacturing, donor sourcing, collection, processing, quality control, and storage practices that yield consistent hemagglutination performance across all required animal species. The products must demonstrate compatibility with the Influenza Division's validated assay protocols and preserve comparability with historical antigenic characterization data used for routine influenza surveillance, FluView reporting, and influenza vaccine strain selection.
Lampire Biological Laboratories is the only known manufacturer whose turkey, chicken, guinea pig, and horse RBCs have been validated for these established CDC HI assay protocols and have consistently demonstrated the performance characteristics required to maintain continuity of longitudinal surveillance data. Use of RBCs from another manufacturer would require extensive validation to establish equivalency and assess impacts on assay performance and historical data comparability. Until such equivalency is demonstrated, no other manufacturer's products will satisfy the Government's minimum requirement to support uninterrupted, consistent influenza surveillance.
No solicitation will be published for this requirement. This notice is issued solely to determine whether there are any responsible sources capable of meeting the Government's requirements.
This notice of intent is not a request for competitive quotations; however, all capability statements, or responses received within five (5) days of the issuance of this notice shall be considered by the Government. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement.
Any capability statement, or response should be emailed to the Contract Specialist, Ada Torres Vega, at cbp0@cdc.gov no later than August 4, 2026, at 3:00 p.m. Eastern Time (ET).
Award Overview
No prior contract identified
No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.
Contacts
Contracting Officer
Primary Contact
Secondary Contact
Documents
No documents available.
Lifecycle
- 3Version 3Combined Synopsis/SolicitationArchivedCurrent
Notice of Intent to Sole Source the Procurement of Weekly Delivery of Turkey, Chicken, Guinea Pig, and Horse Red Blood Cells
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
(i)This is a combined synopsis/solicitation for commercial items prepared in accordancewith the format in FAR Subpart 12.6, as supplemented with additional information includedin this notice. This announcement constitutes the only solicitation; proposals are beingrequested, and a separate written solicitation will not be issued. (ii)The solicitation number is 75N98027Q00017. This solicitation is issued as a Notice ofIntent (NOI) for a non-competitive combined synopsis/solicitation to award a contract orpurchase order without providing for full and open competition (including brand-name, ifapplicable). This acquisition is conducted under the authority of FAR 12.603, Streamlined Solicitation for Commercial Products or Commercial Services, and is not expected to exceed the simplified acquisition threshold. Additional authority includes 41 U.S.C. 1901 and FAR 6.302-3(a)(2)(ii). The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, intends to negotiate and award a purchase order on a non-competitive basis to Purdue University, Purdue Institute for Drug Discovery (DRUG), 575 Stadium Mall Drive, West Lafayette, IN 47907, for the synthesis, scale-up, and characterization of lead Spleen Tyrosine Kinase (SYK) inhibitors in support of the NIH Bench-to-Bedside study "Developing Red Cell-Specific Spleen Tyrosine Kinase (SYK) Inhibitors for Treating Sickle Cell Disease." Rationale for non-competitive award: The proposed acquisition is a continuation of project-specific medicinal chemistry work under the NIH Bench-to-Bedside study "Developing Red Cell-Specific Spleen Tyrosine Kinase (SYK) Inhibitors for Treating Sickle Cell Disease." Dr. Philip S. Low's laboratory at Purdue University is the identified extramural medicinal chemistry collaborator for this project and has performed the prior design and synthesis work associated with the SYK inhibitor candidates being advanced under the study. The Year 1 requirement is specifically for the synthesis, scale-up, and characterization of lead SYK inhibitors S1115 and S1213 for subsequent biological evaluation by NIH investigators. Purdue possesses the project-specific knowledge and experience associated with these compounds. Use of another source would require duplication of prior research before the source could continue the current effort, resulting in delay and technical risk. Based on these circumstances, Purdue University is the only source reasonably available to perform this specific Year 1 requirement. (iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2026-01, effective 03/13/2026. (iv) The associated NAICS code is 325411, Medicinal and Botanical Manufacturing, and the small business size standard is 1,250 employees. This requirement is not set aside for small business. | 73% | Combined Synopsis | 11/04/2026 |
The following VISN 12 Locations have a need for delivery of Blood and Blood Products. Jesse Brown VAMC, 820 South Damen Ave, Chicago, IL 60612 Lovell Federal Health Care Center, 3001 Green Bay Road, North Chicago, IL 60064 Hines VAMC, 5000 South 5th Ave, Hines, IL 60141 William S Middleton VAMC, 2500 Overlook Terrace, Madison, WI 53705. Tomah VAMC, 500 E. Veterans Street, Tomah, WI 54660 Zablocki VAMC, 5000 W. National Ave, Milwaukee WI 53295. The Blood and Blood Products will be defined in RFQ# 36C25226Q0606. | 68% | Awarded | Open |
The following VISN 12 Locations have a need for delivery of Blood and Blood Products. Jesse Brown VAMC, 820 South Damen Ave, Chicago, IL 60612 Lovell Federal Health Care Center, 3001 Green Bay Road, North Chicago, IL 60064 Hines VAMC, 5000 South 5th Ave, Hines, IL 60141 William S Middleton VAMC, 2500 Overlook Terrace, Madison, WI 53705. Tomah VAMC, 500 E. Veterans Street, Tomah, WI 54660 Zablocki VAMC, 5000 W. National Ave, Milwaukee WI 53295. The Blood and Blood Products will be defined in RFQ# 36C25226Q0606. | 67% | Awarded | Open |
The following VISN 12 Locations have a need for delivery of Blood and Blood Products. Jesse Brown VAMC, 820 South Damen Ave, Chicago, IL 60612 Lovell Federal Health Care Center, 3001 Green Bay Road, North Chicago, IL 60064 Hines VAMC, 5000 South 5th Ave, Hines, IL 60141 William S Middleton VAMC, 2500 Overlook Terrace, Madison, WI 53705. Tomah VAMC, 500 E. Veterans Street, Tomah, WI 54660 Zablocki VAMC, 5000 W. National Ave, Milwaukee WI 53295. The Blood and Blood Products will be defined in RFQ# 36C25226Q0606. | 66% | Awarded | Open |
Egg-Free Influenza Vaccine Solicitation: SPE2DP26R0004 | 59% | Solicitation | 12/03/2026 |
Additional Details
Solicitation Number
75D301-26-R-73503
Archive Date
Aug 5, 2026
Office Address
ATLANTA, GA, 30333